Incyte’s product portfolio
Incyte’s (INCY) product portfolio includes the targeted therapies and immunotherapies for the treatment of oncology and non-oncology diseases.
Incyte’s product portfolio includes 17 molecular targets and 19 clinical candidates as of July 31.
The chart above shows Incyte’s collaboration revenues since the first quarter of 2017.
Incyte’s non-oncology products include two drugs: baricitinib and ruxolitinib.
Olumiant (baricitinib) is approved for the treatment of rheumatoid arthritis and is under clinical trials for the treatment of systemic lupus erythematosus and psoriatic arthritis. It’s also involved in a pivotal study for the treatment of atopic dermatitis. Eli Lilly and Company (LLY) holds the exclusive worldwide development and commercialization rights for Olumiant.
Eli Lilly also holds the development and commercialization rights for ruxolitinib for the treatment of graft-versus-host disease in the United States, while Novartis (NVS) holds the development and commercialization rights for ruxolitinib outside the United States.
Incyte has classified its oncology product portfolio based on the therapies used for curing the diseases. These categories include immuno-oncology therapies as well as targeted anticancer therapies.
Immunotherapies are the products that target the patient’s immune system to fight the cancer cells. The products under Incyte’s immunotherapy portfolio include epacadostat and other drugs.
Incyte’s targeted anticancer therapies target cancer cells while causing minimal damage to normal cells. The products in the company’s targeted therapies portfolio include Jakafi (ruxolitinib), Iclusig, Itacitinib, and a few others.
Iclusig is approved for patients with Philadelphia-chromosome positive acute lymphoblastic leukemia and chronic myeloid leukemia.